How to buy, sell and short Moderna shares
Moderna shares are traded around the world. As a result, the US biotech firm is on the radar of many investors in the UK. Read on to learn about buying, selling and shorting Moderna shares using the IG platform.
What's on this page?
How to buy or invest in Moderna shares
There is one wayy to buy Moderna shares – via derivatives trading
Derivatives, such as CFDs, allow you to speculate on upward or downward share price movements without ever taking ownership of any physical shares.
Follow these steps to trade or invest in Moderna shares:
Buying Moderna shares
- Create or log in to your trading account
- Decide whether you want to trade CFDs
- Search for ‘Moderna’ in the search panel
- Choose your position size
- Confirm the trade and monitor your position
If you don’t want to take ownership of Moderna shares, you can speculate on the share price with derivatives in order to:
- Get full exposure with a 20%-25% deposit on almost all of our tier one shares1
- Hedge your positions with CFDs and offset any losses against potential profits
How to sell and short Moderna shares
You can sell physical Moderna shares with us, even if you bought them through another provider – by transferring them to us for free. Or, you can go short on the share price by speculating on downward price movements. The benefits of short-selling include the ability to profit from falling share prices, and the opportunity to hedge against any existing investments or long positions.
Shorting Moderna shares
- Create or log in to your IG trading account
- Decide whether you want to trade CFDs
- Search for ‘Moderna’ in the search panel
- Choose your position size
- Confirm the trade and monitor your position
Moderna’s live market price
Moderna shares are listed on the NASDAQ under the ticker MRNA, where it is a constituent of the Nasdaq 100. It is also listed on the MSCI US Equity Indexes.
Moderna’s stock has performed well since the company floated on the Nasdaq Global Select Market in December 2018, but the stock price soared after the biotech company had its Covid-19 vaccine approved by the FDA in December 2020. Between 21 February 2020 and 19 February 2021, Moderna’s share price increased by an enormous 858.52%.
In its 2020 full year results, the company revealed that it aimed to supply over a billion doses of its Covid-19 vaccine in 2021, generating revenue of approximately $18.4 billion.
What is Moderna’s business model?
Moderna’s business model is based around the use of mRNA technology to accelerate drug discovery and early vaccine development.
It was the first American firm to launch an effective vaccine for Covid-19. Since the Moderna vaccine was approved by the FDA in December 2020, the company has focused on expanding its distribution pipeline in order to meet global demand.
Moderna believes that mRNA could be used to create a new category of medicines. It is currently running discovery programmes into infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.
Moderna key personnel: who manages the company?
Moderna has filled its executive committee with an international team of medical professionals and corporate veterans.
The key players are:
Stéphane Bancel | Chief executive officer |
Stephen Hoge | President |
Juan Andres | Chief technical operations and quality officer |
Marcello Damiani | Chief digital and operational excellence officer |
Tracey Franklin | Chief human resources officer |
Lori Henderson | General counsel and corporate secretary |
Ray Jordan | Chief corporate affairs officer |
Corinne Le Goff | Chief commercial officer |
David Meline | Chief financial officer |
Tal Zaks | Chief medical officer |
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access